Ross Donehower, MD, FACP
Virginia and D.K. Ludwig Professor in
Clinical Investigation of Cancer
Director, Division of Medical Oncology
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Jeff Geschwind, MD
Director of Interventional Radiology
The Johns Hopkins Hospital
Associate Professor of Radiology, Oncology and Surgery
The Johns Hopkins University School of Medicine
Radiology and Radiological Science
Baltimore, Maryland
Ihab Kamel, MD
Associate Professor of Radiology
The Johns Hopkins University School of Medicine
Radiology and Radiological Science
Baltimore, Maryland
Daniel A. Laheru, MD
Assistant Professor of Medical Oncology
The Johns Hopkins University School of Medicine
Assistant Professor of Medical Oncology
Department of Medical Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Timothy M. Pawlik, MD, MPH
Assistant Professor of Surgery
Johns Hopkins Medicine
The Department of Surgery & Surgical Sciences
The Johns Hopkins Hospital
Baltimore, Maryland
Eden Stotsky, BS, BSNc
Health Educator/Program Coordinator
The Johns Hopkins Colon Cancer Center
Baltimore, Maryland
FACULTY DISCLOSURE STATEMENTS
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Albert Einstein College of Medicine, CCME staff, has no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
The Faculty of this program have indicated the following disclosure information:
Michael A. Choti, MD
Consultant: sanofi-aventis
Speakers Bureau: sanofi-aventis and Genentech
Jeff Geschwind, MD
Grant/Research Support: Biocompatibles, Boston Scientific, Genentech, MDS Nordion, and National Institutes of Health/National Cancer Institute (NIH/NCI)
Consultant for: Biocompatibles, Biosphere Medical, Terumo Medical Corporation
Ihab Kamel, MD
Grant/Research Support: Siemens
Ross Donehower, MD, Ronald N. Kaleya, MD, Daniel A. Laheru, MD, Timothy M. Pawlik, MD, and Eden Stotsky, BS, BSNc have nothing to disclose.
OFF-LABEL DISCLOSURE
Jeff Geschwind, MD
Y-90 TheraSpheres (approved for hepatocellular carcinoma under a Humanitarian Device Exemption)
The opinions expressed herein are those of the authors and do not necessarily represent the views of the Albert Einstein College of Medicine, The Johns Hopkins University School of Medicine or sanofi-aventis. Please review complete prescribing information of specific drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |